We then investigated that GSTM3TV2 could promote pancreatic cancer gemcitabine resistance by upregulating L-type amino acid transporter 2 (LAT2) and oxidized low-density lipoprotein receptor 1(OLR1) though competitively sponging let-7. Here, LAT2 is linked to pancreatic neoplasm.